Show source-provided references
18. Amplification of AKT2 in human Pancreatic Cells and Inhibition of AKT2 Expression and Tumorigenicity by Antisense RNA
10.1073/pnas.93.8.3636 ↗21. The Role of Survivin in the Progression of Pancreatic Ductal Adenocarcinoma (PDAC) and a Novel Survivin‐Targeted Therapeutic for PDAC
10.1371/journal.pone.0226917 ↗23. c‐Myc Inhibition and p21 Modulation Contribute to Unsymmetrical Bisacridines‐induced Apoptosis and Senescence in Pancreatic Cancer Cells
10.1007/s43440-024-00658-6 ↗24. Targeted Delivery of C/EBPα‐saRNA by RNA Aptamers Shows Anti‐Tumor Effects in a Mouse Model of Advanced PDAC
10.1016/j.omtn.2019.08.017 ↗25. Targeted Delivery of C/EBPα ‐saRNA by Pancreatic Ductal Adenocarcinoma‐specific RNA Aptamers Inhibits Tumor Growth In Vivo
10.1038/mt.2016.60 ↗26. Targeted Delivery of C/EBPα‐small Activation RNA (saRNA) by RNA Aptamer Inhibits the Growth of Pancreatic Ductal Adenocarcinoma (PDAC) in Vivo
10.1016/S1525-0016(16)33892-8 ↗27. Phase I Multicenter Dose Escalation Study of DCR‐MYC in Patients With Solid Tumors Multiple Myeloma or Lymphoma. ClinicalTrials.gov. Identifier: NCT02110563 https://clinicaltrials.gov/study/NCT02110563. (accessed: August 2025).
28. Phase I Study of LY2181308, an Antisense Oligonucleotide Against Survivin, in Patients with Advanced Solid Tumors
10.1007/s00280-010-1506-7 ↗29. A Randomised Phase 2 Study Combining LY2181308 Sodium (survivin antisense oligonucleotide) with First‐line Docetaxel/Prednisone in Patients with Castration‐Resistant Prostate Cancer
10.1016/j.eururo.2013.10.039 ↗31. TIMEPOINT, a Phase 1 Study Combining MTL‐CEBPA with Pembrolizumab, Supports the Immunomodulatory Effect of MTL‐CEBPA in Solid Tumors
10.1016/j.xcrm.2025.102041 ↗32. Radomised Phase II Study of MTL‐CEBPA Plus Sorafenib or Sorafenib Alone (OUTREACH2) ClinicalTrials.govIdentifier: NCT04710641.https://clinicaltrials.gov/study/NCT04710641(accessed: August 2025).
33. Phase I Study of RNA Oligonucleotide MTL‐CEBPA Atezolizumab and Bevacizumab in Patients With Advanced Hepatocellular Carcinoma ClinicalTrials.govIdentifier: NCT05097911.https://clinicaltrials.gov/study/NCT05097911(accessed: August 2025).
34. Ractigen Therapeutics Announces China NMPA IND Approval for Phase II Clinical Trial of saRNA Therapy RAG‐01 in Non‐Muscle Invasive Bladder Cancer https://www.ractigen.com/ractigen‐therapeutics‐announces‐china‐nmpa‐ind‐approval‐for‐phase‐ii‐clinical‐trial‐of‐sarna‐therapy‐rag‐01‐in‐non‐muscle‐invasive‐bladder‐cancer/(accessed: August 2025).
35. The Human Protein Atlas https://www.proteinatlas.org/ (accessed: January 2025).
36. Development of Transcriptomic Tools for Predicting the Response to Individual Drug of the mFOLFIRINOX Regimen in Patients with Metastatic Pancreatic Cancer
10.3389/fonc.2024.1437200 ↗37. Insights Into the Regulation of Protein Abundance From Proteomic and Transcriptomic Analyses
10.1038/nrg3185 ↗41. Arginine‐terminated Generation 4 PAMAM Dendrimer as an Effective Nanovector for Functional siRNA Delivery in Vitro and in Vivo
10.1021/bc4005156 ↗42. The EPR Effect: Unique Features of Tumor Blood Vessels for Drug Delivery, Factors Involved, and Limitations and Augmentation of the Effect
10.1016/j.addr.2010.04.009 ↗43. Cargo‐Selective and Adaptive Delivery of Nucleic Acid Therapeutics by Bola‐Amphiphilic Dendrimers
10.1073/pnas.2220787120 ↗44. Three‐Dimensional Organotypic Culture: Experimental Models of Mammalian Biology and Disease
10.1038/nrm3873 ↗46. The Third Dimension Bridges the Gap Between Cell Culture and Live Tissue
10.1038/nrm2236 ↗48. Screening Drug Effects in Patient‐Derived Cancer Cells Links Organoid Responses to Genome Alterations
10.15252/msb.20177697 ↗49. Dendrimer Nanosystems for Adaptive Tumor‐Assisted Drug Delivery via Extracellular Vesicle Hijacking
10.1073/pnas.2215308120 ↗